Search hospitals > Washington > Kennewick

Tri-Cities Cancer Center

Claim this profile
Kennewick, Washington 99336
Conducts research for Breast Cancer
Conducts research for Rectal Cancer
Conducts research for Ductal Carcinoma In Situ
Conducts research for Breast cancer
Conducts research for Cervical Cancer
11 reported clinical trials
1 medical researcher
Photo of Tri-Cities Cancer Center in KennewickPhoto of Tri-Cities Cancer Center in KennewickPhoto of Tri-Cities Cancer Center in Kennewick

Summary

Tri-Cities Cancer Center is a medical facility located in Kennewick, Washington. This center is recognized for care of Breast Cancer, Rectal Cancer, Ductal Carcinoma In Situ, Breast cancer, Cervical Cancer and other specialties. Tri-Cities Cancer Center is involved with conducting 11 clinical trials across 26 conditions. There are 1 research doctors associated with this hospital, such as Janice N. Kim.

Area of expertise

1Breast Cancer
Tri-Cities Cancer Center has run 4 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
Stage I
Stage II
2Rectal Cancer
Tri-Cities Cancer Center has run 3 trials for Rectal Cancer.

Top PIs

Janice N. KimSeattle Cancer Care Alliance11 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
4 reported clinical trials
8 drugs studied

Clinical Trials running at Tri-Cities Cancer Center

Oropharyngeal Carcinoma
Oral Squamous Cell Carcinoma
Throat Cancer
Laryngeal Squamous Cell Carcinoma
Squamous Cell Carcinoma
Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria

Similar Hospitals nearby

Select from list below to view details

Frequently asked questions

What kind of research happens at Tri-Cities Cancer Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security